Effect of Age and Lenvatinib Treatment on OS for Patients With Thyroid Cancer

June 4, 2015
Lori J. Wirth, MD

Lori J. Wirth, MD, hematology/oncology, Department of Medicine, Massachusetts General Hospital, discusses the SELECT trial, which examined the effect of age and lenvatinib treatment on overall survival (OS) for patients with 131I-refractory differentiated thyroid cancer.

<<<

View more from the 2015 ASCO Annual Meeting

Lori J. Wirth, MD, hematology/oncology, Department of Medicine, Massachusetts General Hospital, discusses the SELECT trial, which examined the effect of age and lenvatinib treatment on overall survival (OS) for patients with131I-refractory differentiated thyroid cancer.